Want to see AU:M7T full AI Analyst Report?
Top Page
Mach7 Technologies
(Sydney:M7T)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.28
▼(-1.43% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial performance (recurring losses, declining revenue, and negative latest-year operating/free cash flow) and a soft technical trend (below key moving averages with negative MACD). The earnings call provides partial offset through improved cost control, strong gross margins, and signs of second-half commercial momentum, but valuation remains challenged given the loss-making profile and no dividend yield data.
Positive Factors
Recurring Revenue Base
The predominance of recurring revenue and growth in the constant-currency ARR run rate support greater revenue visibility than a purely project-based model. A larger subscription and support base can improve planning, customer retention economics, and the potential for compounding revenue as modules and sites expand.
Negative Factors
Weak and Volatile Profitability
Persistent losses and the deterioration in gross profitability show that Mach7 has not yet established a durable path to positive earnings. Continued negative margins can consume the capital base, constrain investment choices, and make future results more dependent on successful execution and revenue recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue Base
The predominance of recurring revenue and growth in the constant-currency ARR run rate support greater revenue visibility than a purely project-based model. A larger subscription and support base can improve planning, customer retention economics, and the potential for compounding revenue as modules and sites expand.
Read all positive factors
Mach7 Technologies (M7T) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$65.80M
Dividend YieldN/A
Average Volume (3M)86.37K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-17.35%
EPS Growth-47.29%
CountryAU
Employees167
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding235,009,720
10 Day Avg. Volume81,889
30 Day Avg. Volume86,366
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.97
Price to Sales (P/S)2.44
P/FCF Ratio-51.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.40Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$30.45M
Mach7 Technologies Business Overview & Revenue Model
Company Description
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterpris...
How the Company Makes Money
Mach7 Technologies primarily makes money by selling enterprise imaging software to healthcare providers (e.g., hospitals, health systems, and imaging networks). Revenue is generally generated through (1) software licensing or subscription fees for...
Mach7 Technologies Earnings Call Summary
Earnings Call Date:Aug 27, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Mar 03, 2027
Earnings Call Sentiment Positive
The call presented a cautious but constructive tone: FY'26 was framed as a deliberate reset that materially improved the business foundation—higher-quality recurring revenue mix, a 93% gross margin, reduced operating costs, a stronger leadership team, and clear second-half commercial momentum (ARR run rate +7.6% constant currency; H2 revenue +15% vs H1). However, meaningful near-term challenges remain including a 17% reported revenue decline, several sizable customer losses (notably VHA and Trinity Health), an $8.9M net loss, and FX-driven reporting headwinds. Management emphasized stabilization and a roadmap (Flamingo modules, Epic integrations, focused partnerships) to prove growth in FY'27. Overall, positives around margin, cash/no debt, cost discipline and H2 recovery modestly outweigh the lowlights, supporting cautious optimism.Positive Updates
Predominantly Recurring Revenue Base
Total revenue of $27.9M for FY'26 with $23.4M of recurring revenue; contracted ARR (CAR) $25.5M and ARR run rate $23.5M, reflecting a more subscription-driven, predictable revenue mix.
Negative Updates
Year-on-Year Revenue Decline
Total revenue declined 17% versus prior year (as reported), driven primarily by lower capital license revenue and softer professional services.
Read all updates
Q4-2026 Updates
Positive
Negative
Predominantly Recurring Revenue Base
Total revenue of $27.9M for FY'26 with $23.4M of recurring revenue; contracted ARR (CAR) $25.5M and ARR run rate $23.5M, reflecting a more subscription-driven, predictable revenue mix.
Read all positive updates
Company Guidance
Management set four clear FY‑27 priorities—ARR growth, new customer wins, Flamingo adoption and OpEx discipline—and gave FY‑26 baselines to measure progress: FY‑26 total revenue $27.9M (recurring $23.4M), CAR $25.5M and an ARR run‑rate of $23.5M; revenue was down 17% YoY (recurring down 8%), capital license revenue $1.5M (‑17%), while ARR run‑rate was up 7.6% on a constant‑currency basis and CAR was down 9% constant currency. They closed FY‑26 with operating expenses $26.7M (down $5.1M or 16%), gross margin 93%, adjusted EBITDA loss of $0.9M, net loss before amortization $2.9M, net loss after tax $8.9M, cash $19.9M and no debt; cash receipts were $28M and operating cash flow was negative for the year but positive in 3 of 4 quarters (Q1 ‑$3.7M, Q2 ~breakeven, Q3 +$1.2M, Q4 +$1.1M). Second‑half momentum (constant‑currency revenue H2 $15.6M vs H1 $13.5M, +15%), stronger bookings (TCV up 80% H2 vs H1; 86% ARR‑type; 40% of orders in Q4; 21% new logos) and one‑offs (restructuring $1.9M, deferred tax write‑off ≈$1M) provide the starting point for proving recurring revenue growth, module adoption and operating leverage in FY‑27.Mach7 Technologies Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
40
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 27.91M | 33.79M | 17.24M | 30.06M | 27.08M |
| Gross Profit | -1.89M | 8.38M | -6.42M | 9.35M | -2.57M |
| EBITDA | -1.18M | -7.06M | -15.09M | 2.09M | 2.80M |
| Net Income | -8.93M | -6.20M | -7.97M | -1.05M | -4.17M |
Balance Sheet | |||||
| Total Assets | 50.50M | 64.21M | 73.03M | 82.31M | 78.92M |
| Cash, Cash Equivalents and Short-Term Investments | 19.92M | 23.07M | 26.18M | 23.39M | 25.75M |
| Total Debt | 80.39K | 1.12M | 1.27M | 1.20M | 1.33M |
| Total Liabilities | 15.93M | 18.63M | 21.17M | 22.82M | 20.55M |
| Stockholders Equity | 34.56M | 45.58M | 51.86M | 59.48M | 58.38M |
Cash Flow | |||||
| Free Cash Flow | -1.33M | 112.92K | 3.30M | -2.97M | 5.94M |
| Operating Cash Flow | -1.26M | 868.59K | 3.45M | -2.61M | 6.37M |
| Investing Cash Flow | -915.97K | -1.70M | -391.31K | -361.01K | -438.56K |
| Financing Cash Flow | -164.03K | -2.43M | -32.08K | -68.63K | 547.61K |
Mach7 Technologies Technical Analysis
Negative
0.28
Price Trends
0.29
Negative
0.29
Negative
0.36
Negative
Market Momentum
>-0.01
Negative
46.93
Neutral
52.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:M7T, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.29, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.93 is Neutral, neither overbought nor oversold. The STOCH value of 52.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:M7T.
Mach7 Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$18.17B | 68.48 | 63.19% | 0.40% | 22.87% | 130.30% | |
61 Neutral | AU$141.73M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$163.64M | -9.45 | -203.69% | ― | -1.53% | 28.29% | |
49 Neutral | AU$35.44M | -1.91 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$65.80M | -7.37 | -24.29% | ― | -17.35% | -47.29% | |
47 Neutral | AU$682.85M | -24.02 | -30.04% | ― | <0.01% | 2.08% |
* Healthcare Sector Average
AU:M7T
Mach7 Technologies
0.28
-0.03
-11.11%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.20
-0.04
-17.02%
AU:PME
Pro Medicus Limited
173.95
-124.75
-41.76%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.11
-47.83%
AU:AYA
Artrya Limited
4.18
2.00
91.74%
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
Mach7 Technologies Corporate Events
Mach7 Technologies Options Lapse and Expire, Clarifying Capital Structure
Sep 1, 2026
Mach7 Technologies has updated the market on changes to its issued capital following the cessation of certain option securities. The company reported that a tranche of 16,666 options lapsed after their conditions could not be satisfied, while a fu...
Mach7 Technologies Outlines Parameters and Limits of FY26 Results Briefing
Aug 27, 2026
Mach7 Technologies has released its FY26 results presentation, outlining general background information on its activities and financial disclosures as of 28 August 2026. The document emphasizes that the material is informational only, not a prospe...
Mach7 Technologies Files 2026 Preliminary Final Report
Aug 27, 2026
Mach7 Technologies has released its Appendix 4E preliminary final report and audited financial statements for the year ended 30 June 2026. The disclosure, made in line with ASX listing rules, signals completion of the company’s annual report...
Mach7 Technologies Announces Lapse of Conditional Options
Aug 24, 2026
Mach7 Technologies Limited has notified the market of changes to its issued capital following the cessation of certain options on its register. The announcement details the lapse of conditional rights to securities, reflecting adjustments in the c...
Mach7 Options Lapse Reduces Potential Share Dilution
Aug 17, 2026
Mach7 Technologies has updated the market on changes to its capital structure, notifying the cessation of several tranches of options listed under the ASX code M7TAJ. The options, which carried various exercise prices and expiry dates, have lapsed...
Mach7 Technologies sets date for FY26 results and investor webinar
Aug 11, 2026
Mach7 Technologies will release its financial results for the year ended 30 June 2026 on 28 August, underscoring a key reporting milestone for the ASX-listed healthcare software group. The company is positioning its enterprise imaging platform as ...
Mach7 Technologies Presents Enterprise Imaging Strategy at Sharewise Investor Webinar
Jul 7, 2026
Mach7 Technologies has released the presentation to be delivered by Managing Director and CEO Teri Thomas at a Sharewise investor webinar scheduled for 8 July 2026. By participating in the event, investors gain further insight into Mach7’s e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.